X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AVA6000 is a form of doxorubicin that has been chemically modified with Avacta’s pre|CISION platform designed to reduce systemic side effects by targeting the release of active chemotherapy in tumour tissue.
Lead Product(s): Doxorubicin Prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
AVA6000 is a form of doxorubicin that has been chemically modified with Avacta’s pre|CISIONTM platform designed to reduce systemic side effects by targeting the release of active chemotherapy in tumour tissue.
Lead Product(s): Doxorubicin Prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
AVA6000 is a novel form of doxorubicin, first-in-class FAPα activated prodrug that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index.
Lead Product(s): Doxorubicin Prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
AVA6000 is a novel form of doxorubicin (prodrug) that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index.
Lead Product(s): Doxorubicin Prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
AVA6000 is a novel form of doxorubicin (prodrug) that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index.
Lead Product(s): Doxorubicin Prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
AVA3996 is a tumour microenvironment activated proteasome inhibitor, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via fibroblast activation protein-alpha (FAP-a) mediated cleavage.
Lead Product(s): AVA3996
Therapeutic Area: Oncology Product Name: AVA3996
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
AVA6000 is the first-in-class FAPα activated prodrug based on the pre|CISION platform, providing a prodrug form of doxorubicin with an improved safety profile enabling broader use in oncology, particularly in combinations with immuno-oncology drug agents.
Lead Product(s): Doxorubicin Prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
AVA6000 is form of generic chemotherapy doxorubicin that has been modified using the pre|CISION technology so that it is activated predominantly in tumour with aim of sparing healthy tissue from exposure and improving the safety, tolerability and efficacy of drug.
Lead Product(s): FAP Activated Doxorubicin Prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
AVA6000 is a novel form of doxorubicin that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index.
Lead Product(s): Doxorubicin Prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
Under the terms of the agreement, LG Chem has the exclusive rights to develop and commercialise, on a global basis, Avacta’s Affimer® PD-L1 inhibitor (PD-L1 XT) with Affimer XT™ serum half-life extension for a range of indications.
Lead Product(s): PD-L1 XT
Therapeutic Area: Oncology Product Name: PD-L1 XT
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: LG Chem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration June 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
